Genmab A/S (GMAB) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$27.54
Price Target
$39.90
Target Range
$32.00 — $48.00
Analyst Rating
Buy
Forward P/E23.7x
Trailing P/E14.4x
Forward PEG0.82
Implied Growth-89.0%
Median Target$40.00
Analyst Spread40.1%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$32
+16.2%
Consensus
$40
+44.9%
Bull Case
$48
+74.3%
Valuation Model TargetsConfidence: 40/100
Bear$133
Base$197
Bull$390
GMAB Price Target Analysis
Updated May 6, 2026As of May 6, 2026, Genmab A/S (GMAB) has a Wall Street consensus price target of $39.90, based on estimates from 17 covering analysts. With the stock currently trading at $27.54, this represents a potential upside of +44.9%. The company has a market capitalization of $16.96B.
Analyst price targets range from a low of $32.00 to a high of $48.00, representing a 40% spread in expectations. The median target of $40.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 12 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, GMAB trades at a trailing P/E of 14.4x and forward P/E of 23.7x. The forward PEG ratio of 0.82 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow -89.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $196.97, with bear and bull scenarios of $133.02 and $389.90 respectively. Model confidence stands at 40/100, suggesting limited visibility into future performance.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+16.7%
Avg Forward P/E18.5x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 REGNRegeneron Pharmaceuticals, Inc. | $73.0B | $702.33 | $865.68 | +23.3% | Buy | 15.2x | 48 |
 SRPTSarepta Therapeutics, Inc. | $2.3B | $21.79 | $24.63 | +13.0% | Buy | 7.3x | 54 |
 INCYIncyte Corporation | $19.5B | $97.47 | $109.50 | +12.3% | Buy | 13.0x | 44 |
 EXELExelixis, Inc. | $11.3B | $44.42 | $45.71 | +2.9% | Buy | 13.4x | 32 |
 HALOHalozyme Therapeutics, Inc. | $7.8B | $65.87 | $78.33 | +18.9% | Buy | 8.2x | 27 |
 ABBVAbbVie Inc. | $364.6B | $206.15 | $256.64 | +24.5% | Buy | 14.5x | 41 |
 BMYBristol-Myers Squibb Company | $116.2B | $56.92 | $62.00 | +8.9% | Hold | 9.0x | 41 |
 MRKMerck & Co., Inc. | $279.5B | $113.16 | $129.31 | +14.3% | Buy | 22.1x | 37 |
 RGENRepligen Corporation | $7.1B | $125.71 | $168.00 | +33.6% | Buy | 63.9x | 23 |
 RCUSArcus Biosciences, Inc. | $2.6B | $26.06 | $30.00 | +15.1% | Buy | — | 18 |
Upside Potential Comparison
RGENABBVREGNHALORCUSMRKSRPTINCYFull GMAB Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See GMAB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GMAB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GMAB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGMAB — Frequently Asked Questions
Quick answers to the most common questions about buying GMAB stock.
What is the GMAB stock price target for 2026?
The consensus Wall Street price target for GMAB is $39.9, representing 44.9% upside from the current price of $27.537. With 17 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is GMAB a buy, sell, or hold?
GMAB has a consensus rating of "Buy" based on 17 Wall Street analysts. The rating breakdown is predominantly bullish, with 12 Buy/Strong Buy ratings. The consensus 12-month price target of $39.9 implies 44.9% upside from current levels.
Is GMAB stock overvalued or undervalued?
GMAB trades at a forward P/E of 23.7429x, representing a moderate valuation. With analysts targeting $39.9 (44.9% implied move), the stock appears reasonably valued with upside.
How high can GMAB stock go?
The most bullish Wall Street analyst has a price target of $48 for GMAB, while the most conservative target is $32. The consensus of $39.9 represents the median expectation. Our quantitative valuation model projects a bull case target of $390 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover GMAB stock?
GMAB is well covered by analysts, with 17 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 12 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the GMAB stock forecast?
The 12-month GMAB stock forecast based on 17 Wall Street analysts shows a consensus price target of $39.9, with estimates ranging from $32 (bear case) to $48 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $197, with bear/bull scenarios of $133/$390.
What is GMAB's fair value based on fundamentals?
Our quantitative valuation model calculates GMAB's fair value at $197 (base case), with a bear case of $133 and bull case of $390. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 40/100.
What is GMAB's forward P/E ratio?
GMAB trades at a forward P/E ratio of 23.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 14.4x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy GMAB stock?
Wall Street analysts are very optimistic on GMAB, with a "Buy" consensus rating and $39.9 price target (44.9% upside). 12 of 17 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do GMAB price targets vary so much?
GMAB analyst price targets range from $32 to $48, a 40% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $39.9 consensus represents the middle ground. Our model's $133-$390 range provides an independent fundamental perspective.